Lenkiewicz’s study of adenosquamous carcinoma of the pancreas suggested that mutations in the KRAS gene provide a therapeutic target for adenosquamous carcinoma [30], which may provide new directions for the treatment of colorectal adenosquamous carcinoma. This evidence concerns the gene KRAS and colorectal adenosquamous carcinoma.